Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Payables (2016 - 2025)

Rocket Pharmaceuticals' Payables history spans 10 years, with the latest figure at $27.3 million for Q4 2025.

  • For Q4 2025, Payables fell 27.85% year-over-year to $27.3 million; the TTM value through Dec 2025 reached $27.3 million, down 27.85%, while the annual FY2025 figure was $27.3 million, 27.85% down from the prior year.
  • Payables for Q4 2025 was $27.3 million at Rocket Pharmaceuticals, down from $28.3 million in the prior quarter.
  • Across five years, Payables topped out at $45.8 million in Q4 2023 and bottomed at $19.6 million in Q4 2021.
  • The 5-year median for Payables is $30.4 million (2023), against an average of $30.7 million.
  • The largest annual shift saw Payables surged 102.74% in 2021 before it plummeted 47.5% in 2022.
  • A 5-year view of Payables shows it stood at $19.6 million in 2021, then skyrocketed by 86.9% to $36.7 million in 2022, then grew by 24.9% to $45.8 million in 2023, then decreased by 17.39% to $37.8 million in 2024, then decreased by 27.85% to $27.3 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Payables are $27.3 million (Q4 2025), $28.3 million (Q3 2025), and $40.5 million (Q2 2025).